GIANT CELL ARTERITIS
Clinical trials for GIANT CELL ARTERITIS explained in plain language.
Never miss a new study
Get alerted when new GIANT CELL ARTERITIS trials appear
Sign up with your email to follow new studies for GIANT CELL ARTERITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Cheaper drug may match expensive biologic in artery disease trial
Disease control OngoingThis study compares two treatments—methotrexate and tocilizumab—for giant cell arteritis, a disease that causes inflamed arteries and can lead to vision loss. Both drugs aim to prevent relapses and reduce the need for long-term steroids, which have serious side effects. About 230…
Matched conditions: GIANT CELL ARTERITIS
Phase: PHASE3 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Best way to stop arthritis drug may prevent relapses
Disease control OngoingThis study looks at 120 adults with giant cell arteritis (GCA) who are stable on tocilizumab. It compares stopping the drug all at once versus gradually tapering it off. The goal is to see which approach better prevents the disease from flaring up again. Researchers hope to find …
Matched conditions: GIANT CELL ARTERITIS
Phase: PHASE3 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New imaging methods could transform PMR diagnosis
Diagnosis OngoingThis study explores whether ultrasound and PET/CT scans can accurately diagnose and monitor polymyalgia rheumatica (PMR), a condition causing muscle pain and inflammation. Researchers will follow 98 adults over 50 suspected of having PMR, using imaging at the start, after 8 weeks…
Matched conditions: GIANT CELL ARTERITIS
Sponsor: Kresten Krarup Keller • Aim: Diagnosis
Last updated May 15, 2026 11:57 UTC